MTTI is a privately held biotechnology company translating novel radiopharmaceuticals for disease treatment and diagnosis. TDURA (TumorVue®), based on radiolabeling the targeting molecule, duramycin, is MTTI’s most advanced platform technology with multiple clinical applications. They include: early detection of tumor response to chemotherapy (in one day), cardiotoxicity, atherosclerotic plaque, systemic inflammatory response syndrome (SIRS) and transplant rejection. Tc-99m, Ga-68, F-18 and Cu-64-duramycin and a wide range of fluorescent analogs are under development. Therapeutic molecules under development include: 131I-SapC-DOPS for glioblastoma multiforme (GBM) and 177Lu-DOTA-X-TATE for neuroendocrine tumors. These therapeutics are backed by extensive published data, the FDA Orphan Drug designations and an ongoing Phase I clinical trial.